BPC-157
A synthetic 15-amino-acid fragment of a stomach protein heavily discussed for tendon and gut healing, but almost entirely lacking controlled human clinical trials.
Angiogenesis & Focal Adhesion Signaling
In laboratory and rodent models, BPC-157 stimulates the growth of new microscopic blood vessels and cell motility in poorly vascularized soft tissue.
Observed in Animal Models (Rats & Mice)
- ✓VEGF Upregulation: Sprouting of collateral capillaries into transected Achilles tendons.
- ✓FAK-Paxillin Pathway: Accelerated migration of tendon fibroblasts to injury sites.
- ✓Gastric Cytoprotection: Accelerates healing of chemical stomach ulcers in rodents.
Human Clinical Evidence Reality Check
- ✕Zero Phase 3 Human Trials: No completed randomized controlled trials in orthopedic medicine.
- ✕FDA Category 2 Compounding Alert: Flagged by FDA for potential immunogenicity and angiogenic risks.
- ✕WADA Prohibited: Banned at all times in competitive sports under Category S2.
What is BPC-157?
BPC-157 (Body Protection Compound 157) is a synthetic 15-amino-acid peptide derived from a naturally occurring protective protein sequence found in human gastric juice. It is chemically stable in stomach acid and has been studied in laboratory models for tissue repair.
Why are people interested in it?
BPC-157 is widely discussed in fitness, athletic, and biohacking communities for accelerating the healing of soft tissue injuries — including torn tendons, sprained ligaments, muscle tears, and inflammatory gut conditions like ulcers or colitis.
Primary Research Categories
- Peptide fragments
- Preclinical research compounds
How does it work in the body?
Preclinical laboratory studies indicate that BPC-157 promotes tissue healing through several biological pathways, most notably angiogenesis (the growth of new blood vessels) and the recruitment of repair cells to injury sites.
Proposed Cellular Mechanism (Laboratory Models)
Angiogenesis & Fibroblast Migration Pathways
In animal and cell-culture experiments, BPC-157 is observed to upregulate growth factor signaling and facilitate tissue regeneration through three primary actions:
1. VEGF Receptor Activation
Promotes vascular endothelial growth factor receptor upregulation, driving new microvascular capillary sprout formation into injured tendon and ligament tissues.
2. FAK-Paxillin Phosphorylation
Activates focal adhesion kinase signaling, stimulating tendon fibroblasts to migrate toward defect sites and produce organized collagen fibers.
3. Nitric Oxide Homeostasis
Interacts with nitric oxide synthases to modulate tissue perfusion, protect gastric mucosa, and support blood flow regulation during acute trauma.
Angiogenesis Stimulation (VEGF Pathway)
Promotes the formation of new microscopic capillary networks into damaged, poorly vascularized tissue like tendons.
Cell Migration (FAK-Paxillin Pathway)
Upregulates repair protein signaling, allowing tendon fibroblasts and endothelial cells to move toward injury sites.
Nitric Oxide (NO) Modulation
Normalizes local blood flow and vascular tone during acute tissue trauma.
Nitric Oxide & Mucosal Defense
Stabilizes the stomach and intestinal mucosal lining against chemical and inflammatory injury.
Key Distinction: These biological mechanisms have been demonstrated in cell cultures and rodent animal models. Whether they occur identically in living human tissue remains unproven in published clinical trials.
What has actually been demonstrated in humans?
The published scientific literature on BPC-157 consists almost exclusively of in vitro (cell culture) assays and animal studies (primarily surgically injured rats and mice). There are zero completed, peer-reviewed Phase 3 human clinical trials demonstrating that BPC-157 safely or effectively heals injuries in human patients.
Pharmaceutical Reality vs. Unregulated Research Chemicals
BPC-157 is not approved by the FDA or any global drug authority. In 2023, the FDA placed BPC-157 on the Category 2 compounding restriction list, citing significant potential risks including immunogenicity and unexpected blood vessel proliferation. The World Anti-Doping Agency (WADA) strictly prohibits BPC-157 at all times.
What is still uncertain or unknown?
Human pharmacokinetics, half-life, systemic absorption from oral ingestion, and proper therapeutic dosing ranges in humans are completely uncharacterized. Controlled human trial data for musculoskeletal injuries or inflammatory bowel disease is absent.
Clinical Perspectives & Expert Discussions
Explore all perspectivesWhat identifiable clinicians, researchers, and professional bodies have publicly discussed regarding BPC-157.
Dr. Brad Stanfield, MBChB
MBChB (University of Auckland School of Medicine); registered General Practitioner in New Zealand; clinical trial investigator and medical educator.
Dr. Stanfield provides critical appraisal of popular biohacking peptides (notably BPC-157, TB-500, and Epitalon), highlighting that the overwhelming majority of claims circulate on rodent and cell-culture data that have never been verified in rigorous human randomized controlled trials. He warns that online suppliers often sell unpurified chemicals with significant batch variability and unknown long-term human toxicity.
U.S. FDA Pharmacy Compounding Advisory Committee (PCAC)
Federal scientific advisory committee composed of physicians, toxicologists, pharmacologists, and compounding experts.
FDA briefing materials presented to the PCAC advised against including BPC-157 and TB-500 on the 503A bulks compounding list. FDA scientists highlighted serious safety concerns, including lack of human pharmacokinetic and exposure data, potential immunogenicity (formation of anti-drug antibodies), and the risk of uncharacterized peptide-related peptide impurities arising during complex chemical synthesis.
Dosing Reference
Open BPC-157 Dosing ReferenceNo approved product and no registered human trials in this file. The only human data indexed are a small retrospective case series; animal literature is extensive but comes from largely one research network.
Therapept separates official product labels, published clinical study interventions, animal research, clinical references, and community-reported ranges — never blended into one number.
Research at a Glance
Open the full evidence file (9 records)9 records in this file
- HUMAN DATA1
- ANIMAL1
- IN VITRO1
- REVIEW3
- REGULATORY3
Publication span: 2003–2026
What Has Actually Been Studied
- FDA PCAC briefing — BPC-157-related bulk drug substances (23 July 2026) (FDA PCAC briefing, 2026) — FDA advisory-committee briefing.
- FDA table of bulk drug substances nominated for compounding and subsequently withdrawn (FDA compounding communications, 2026) — Regulatory listing.
- Injectable peptide therapy: a primer for orthopaedic and sports medicine physicians (The American Journal of Sports Medicine, 2026) — Narrative review.
- Peptide supplements and their therapeutic applications in sports medicine (The American Journal of Sports Medicine, 2026) — Scoping review.
Plus 5 more records in the evidence file.
What is Still Unknown
What we know
- A substantial preclinical literature, much of it from one research network, reports effects in rodent models of tendon, gut and other injury.
- No FDA-approved drug product exists. The substance is on FDA's withdrawn compounding-nominations table and is named on the WADA Prohibited List (S0).
- Independent sports-medicine reviews in 2026 describe the human clinical literature as inadequate for clinical inference.
Editorial reading of the records below, labelled as Therapept analysis. How records are built
What remains uncertain
- Whether rodent findings translate to humans under controlled conditions.
- How much of the preclinical corpus has been replicated outside the originating network.
- Whether commercial research-use material matches the material used in published experiments — a documentation question, not a study result.
Combinations and Stacks
- BPC-157 + TB-500
Discussed as a pairing of two compounds with connective-tissue research histories — BPC-157 for tendon, ligament, gut and muscle models; TB-500 as a fragment of thymosin β4, whose full-length parent has wound-healing literature.
Preparation and Handling
Lyophilized peptides ship as freeze-dried powders; whatever happens next involves diluents, concentrations and storage conditions that are compound- and product-specific.
United States Regulatory Status
No FDA-approved product
- No approved drug product exists in Drugs@FDA.
- Listed on FDA's table of bulk substances nominated for compounding and subsequently withdrawn by the nominator. FDA's published concerns include immunogenicity risk, peptide-related impurities, and complexity of API characterisation.
- On 23 July 2026 PCAC discussed BPC-157 (free base) and BPC-157 acetate (use evaluated: ulcerative colitis). FDA briefing materials proposed that they NOT be included on the 503A Bulks List. Nominations had been withdrawn; FDA elected to proceed. Committee recommendations are non-binding; FDA has not published a listing decision as of this review.
- Not on the 503A Bulks List.
WADA Anti-Doping Status
Named in Class S0 (Non-Approved Substances). Prohibited at all times; Specified Substance.
Technical Chemical SpecificationsClick to view CAS, sequence, and molecular formulas
- Molecular weight
- 1419.5 g/mol
- Sequence length
- 15 chars
- CAS number
- 137525-51-0
- PubChem CID
- 9941957
- Compound class
- Synthetic 15-residue peptide corresponding to a partial sequence of human gastric juice protein BPC
- Sequence
- GEPPPGKPADDAGLV
- Molecular formula
- C62H98N16O22
- Molecular weight
- 1419.5 g/mol
- CAS number
- 137525-51-0
- PubChem CID
- 9941957
Sources
Last reviewed 12 September 2026 · Compiled by Therapept Editorial · How these records are built